Literature DB >> 33223079

Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.

Cynthia Bodkin1, Robert M Pascuzzi2.   

Abstract

Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the most common disorders of neuromuscular transmission in clinical practice. Disorders of the neuromuscular junction (NMJ) are characterized by fluctuating and fatigable weakness and include autoimmune, toxic, and genetic conditions. Adults with NMJ disorders are most often antibody mediated, with MG being the most common, having a prevalence of approximately 1 in 10,000, and with women being affected about twice as often as men. This article focuses on advances in management of autoimmune MG and LEMS.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complement inhibitor; Lambert Eaton myasthenic syndrome; Myasthenia gravis; Thymectomy; Weakness

Year:  2020        PMID: 33223079     DOI: 10.1016/j.ncl.2020.09.007

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  2 in total

1.  Efficacy and safety of Buzhong Yiqi decoction combined with western medicine in the treatment of myasthenia gravis: A protocol for systematic review and meta-analysis.

Authors:  Gang Zong; Shiliang Liu; Zunling Chen; Yulei Hu
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

2.  Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients.

Authors:  Xin Huang; Hao Ran; Yingkia Li; Qian Ma; Changyi Ou; Li Qiu; Huiyu Feng; Weibin Liu
Journal:  Front Neurol       Date:  2022-09-09       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.